Form 4: RA Capital Increases Stake in Artiva Biotherapeutics

RA Capital Management has acquired 6.5 million shares and 2.17 million pre-funded warrants in Artiva Biotherapeutics.

Summary

• RA Capital Management, L.P. reported the acquisition of 6,510,416 shares of Artiva Biotherapeutics (ARTV) common stock at a price of $11.52 per share.
• The firm also acquired 2,170,138 pre-funded warrants at a price of $11.5199 per warrant.
• The transactions occurred on May 11, 2026.
• Following these transactions, RA Capital holds a significant beneficial interest in the company, with 15,203,995 shares held by the Fund and additional holdings across other managed entities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as it reflects a major institutional investor increasing its commitment to the company through a significant capital injection.

Positives

• Strong signal of institutional confidence from a major healthcare-focused investment firm.
• Significant capital injection into the issuer through the purchase of common stock and warrants.
• Alignment of interests as RA Capital maintains board representation via Laura Stoppel.

Negatives

• Increased concentration of ownership by a single institutional investor may impact future liquidity.
• Potential for future dilution if pre-funded warrants are exercised, subject to ownership caps.

Risks

• Ownership is subject to a 9.99% beneficial ownership cap regarding the exercise of pre-funded warrants.
• Market volatility associated with biotech equity investments.
• Reliance on the continued strategic support of the lead investor.

Future Outlook

The acquisition of pre-funded warrants suggests an expectation of long-term value appreciation, with the warrants being exercisable immediately subject to a 9.99% ownership threshold.

Management Comments

• The reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that large-scale follow-on investments by specialized healthcare funds like RA Capital are common in the biotech sector to support clinical development milestones and provide runway for emerging therapies.

Comparison to Industry Standards

• The transaction structure involving pre-funded warrants is a standard mechanism in biotech private placements to allow investors to increase stakes while managing regulatory ownership thresholds.
• The involvement of RA Capital is consistent with their historical strategy of taking significant positions in clinical-stage biotechnology companies.

Corporate Governance

Related Party Transactions

• RA Capital Management, L.P. acts as the investment manager for the funds involved in the transaction.

Stakeholder Impact

• Shareholders benefit from the validation provided by a major institutional investor's capital commitment.
• The company gains additional financial resources to support its operations.

Next Steps

• Potential exercise of pre-funded warrants by RA Capital, subject to the 9.99% ownership limitation.

Key Dates

Recommendation

The significant capital commitment from a sophisticated healthcare investor like RA Capital often serves as a catalyst for positive market sentiment and provides the company with necessary liquidity to advance its pipeline.

Keywords

Artiva Biotherapeutics, ARTV, RA Capital Management, Biotech, Insider Trading, Form 4, Equity Financing